The comparative sensitivity of three in vitro safety pharmacology models for the detection of lidocaine-induced cardiac effects

Journal of Pharmacological and Toxicological Methods

Volumn 66, Issue 1, 2012, Pages 52-58

  Goineau, Sonia ^a   Castagné, Vincent ^a   Guillaume, Philippe ^a   Froget, Guillaume ^a  

^a Porsolt ^*  (France)

Author keywords

Arrhythmia; Atria; Cardiac safety pharmacology; Conduction; HNav 1.5 current; Purkinje fiber

Indexed keywords

LIDOCAINE; SODIUM CHANNEL NAV1.5;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SAFETY; EMBRYO; ENVIRONMENTAL TEMPERATURE; GUINEA PIG; HEART ATRIUM; HEART CONDUCTION; HEART CONTRACTION; HEART DEPOLARIZATION; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PATCH CLAMP; PURKINJE CELL; PURKINJE FIBER; RABBIT; SODIUM CURRENT;

ACTION POTENTIALS; ANIMALS; ATRIAL FUNCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HEART; HEART ATRIA; HEK293 CELLS; HUMANS; LIDOCAINE; MALE; PATCH-CLAMP TECHNIQUES; PURKINJE FIBERS; RABBITS; SENSITIVITY AND SPECIFICITY; TOXICITY TESTS; TRANSFECTION; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS;

CAVIA; ORYCTOLAGUS CUNICULUS;

EID: 84864077856     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.06.001     Document Type: Article

References (38)

1. Antzelevitch C., Burashnikov A. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. Journal of Electrocardiology 2009, 42:543-548.
2. Balser J.R. The cardiac sodium channel: Gating function and molecular pharmacology. Journal of Molecular and Cellular Cardiology 2001, 33:599-613.
3. Bigger J.T., Mandel W.J. Effect of lidocaine on the electrophysiological properties of ventricular muscle and Purkinje fibers. Journal of Clinical Investigation 1970, 49:63-77.
4. Burashnikov A., Di Diego J.M., Zygmunt A.C., Belardinelli L., Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007, 116:1449-1457.
5. Campbell T.J. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovascular Research 1983, 17:344-352.
6. Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New England Journal of Medecine 1989, 321:406-412.
7. Cardiac Arrhythmia Suppression Trial-II Investigators Effect of antiarrhythmic agent moricizine on survival after myocardial infarction: The Cardiac Arrhythmia Suppression Trial-II. New England Journal of Medecine 1992, 327:227-233.
8. Chen M.X., Helliwell R.M., Clare J.J. In vitro profiling against ion channels beyond hERG as an early indicator of cardiac risk. Current Opinion in Molecular Therapeutics 2009, 11:269-281.
9. Colatsky T.J. Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers. An effect on steady state sodium currents?. Circulation Research 1982, 50:17-27.
10. Ducroq J., Printemps R., Guilbot S., Gardette J., Salvetat C., Le Grand M. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies. Journal of Pharmacological and Toxicological Methods 2007, 56:159-170.
11. Erdemli G., Kim A.M., Ju H., Springer C., Penland R.C., Hoffmann P.K. Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation. Frontiers in Pharmacology 2012, 3:6.
12. Fozzard H.A., January C.T., Makielski J.C. New studies of the excitatory sodium currents in heart muscle. Circulation Research 1985, 56:475-485.
13. Gintant G.A., Gallacher D.J., Pugsley M.K. The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation. British Journal of Pharmacology 2011, 164:254-259.
14. Hamill O.P., Marty A., Neher E., Sakmann B., Sigworth F.J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Archiv 1981, 391:85-100.
15. + channel and drug-induced prolongation of the QRS complex. British Journal of Pharmacology 2011, 164:260-273.
16. Heist E.K., Ruskin J.N. Drug-induced arrhythmia. Circulation 2010, 122:1426-1435.
17. ICH Harmonized Tripartite Guideline (S7A) Safety Pharmacology Studies for human Pharmaceuticals Available from. http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
18. ICH Harmonized Tripartite Guideline (S7B) The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals Available from. http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
19. Ito K., Nagafuchi K., Taga A., Yorikane R., Koike H. Possible involvement of altered Na+ -Ca2+ exchange in negative inotropic effects of class I antiarrhythmic drugs on rabbit and rat ventricles. Journal of Cardiovascular Pharmacology 1996, 27:355-361.
20. Larbig R., Torres N., Bridge J.H., Goldhaber J.I., Philipson K.D. Activation of reverse Na+-Ca2+ exchange by the Na+ current augments the cardiac Ca2+ transient: evidence from NCX knockout mice. The Journal of Physiology 2010, 588:3267-3276.
21. Lu H.R., Mariën R., Saels A., De Clerck F. Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. Journal of Cardiovascular Electrophysiology 2001, 12:93-102.
22. Lu H.R., Rohrbacher J., Vlaminckx E., Van Ammel K., Yan G.X., Gallacher D.J. Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers. British Journal of Pharmacology 2010, 160:60-76.
23. Moeller C. Keeping the Rhythm: hERG and beyond in Cardiovascular Safety Pharmacology. Expert Review of Clinical Pharmacology 2011, 3:321-329.
24. Nerbonne J.M., Kass R.S. Molecular physiology of cardiac repolarization. Physiological Reviews 2005, 85:1205-1253.
25. Picard S., Goineau S., Guillaume P., Henry J., Hanouz J.L., Rouet R. Supplemental Studies for Cardiovascular Risk Assessment in Safety Pharmacology: A Critical Overview. Cardiovascular Toxicology 2011, 11:285-307.
26. Picard S., Goineau S., Rouet R. The action potential of the Purkinje fiber: An in vitro model for evaluation of the proarrhythmic potential of cardiac and non cardiac drugs. Current Protocols in Pharmacology 2006, (Chapter 11, Unit 11.3).
27. Roche M., Renauleaud C., Ballet V., Doubovetzky M., Guillon J.M. The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability. Journal of Pharmacological and Toxicological Methods 2010, 61:238-250.
28. Sanguinetti M.C., Jiang C., Curran M.E., Keating M.T. A mechanistic link between an inherited and anacquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995, 81:299-307.
29. Sanguinetti M.C., Jurkiewicz N.K. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. Journal of General Physiology 1990, 96:195-215.
30. Schram G., Pourrier M., Melnyk P., Nattel S. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circulation Research 2002, 90:939-950.
31. Sheets M.F., Hanck D.A., Fozzard H.A. Nonlinear relation between Vmax and INa in canine cardiac Purkinje cells. Circulation Research 1988, 63:386-398.
32. Shirayama T., Inoue D., Inoue M., Tatsumi T., Yamahara Y., Asayama J., Katsume H., Nakagawa M. Electrophysiological effects of sodium channel blockers on guinea pig left atrium. Journal of Pharmacology and Experimental Therapeutics 1991, 259:884-893.
33. Tamargo J., Caballero R., Gomez R., Valenzuela C., Delpon E. Pharmacology of cardiac potassium channels. Cardiovascular Research 2004, 62:9-33.
34. Valentin J.P. Reducing QT liability and proarrhythmic risk in drug discovery and development. British Journal of Pharmacology 2010, 159:5-11.
35. Wang Z.G., Pelletier L.C., Talajic M., Nattel S. Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation 1990, 82:274-283.
36. Wang Q., Shen J., Splawski I., Atkinson D., Li Z., Robinson J.L., Moss A.J., Towbin J.A., Keating M.T. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995, 80:805-811.
37. Warner B., Hoffmann P. Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug Reactions and Toxicological Reviews 2002, 21:189-203.
38. Wilde A.A., Langendijk P. Antiarrhythmic drugs, patients, and the pharmaceutical industry: Value for patients, physicians, pharmacists or shareholders?. Netherlands Heart Journal 2007, 15:127-128.